869112-14-1

Basic information

• Product Name: 4-Piperidinecarboxylic acid, 1-(2-chloroethyl)-, ethyl ester
• Synonyms: 4-Piperidinecarboxylic acid, 1-(2-chloroethyl)-, ethyl ester;ethyl 1-(2-chloroethyl)piperidine-4-carboxylate
• CAS NO: 869112-14-1
• Molecular Formula: C₁₀H₁₈ClNO₂
• Molecular Weight: 219.70842
• Mol File: 869112-14-1.mol

Chemical Properties

• Boiling Point: 279.7±35.0 °C(Predicted)
• Appearance: /
• Density: 1.095±0.06 g/cm3(Predicted)
• PKA: 7.50±0.10(Predicted)
• CAS DataBase Reference: 4-Piperidinecarboxylic acid, 1-(2-chloroethyl)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinecarboxylic acid, 1-(2-chloroethyl)-, ethyl ester(869112-14-1)
• EPA Substance Registry System: 4-Piperidinecarboxylic acid, 1-(2-chloroethyl)-, ethyl ester(869112-14-1)

Safety Data

• Hazardous Substances Data: 869112-14-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Piperidinecarboxylic acid, 1-(2-chloroethyl)-, ethyl ester is used as an intermediate in the synthesis of Umeclidinium Bromide for its potential long-acting antimuscarinic properties, which can be beneficial in treating conditions such as chronic obstructive pulmonary disease (COPD) and overactive bladder.

Upstream product

• 1126-09-6 4-carbethoxypiperidine 
• 107-04-0 1-Bromo-2-chloroethane 
• 75-21-8 oxirane 
• 939900-20-6 C₁₀H₁₉NO₃ 
• 107-20-0 2-chloroethanal 
• 540-51-2 2-bromoethanol 

Downstream Products

• 461648-39-5 α,α-diphenyl-1-azabicyclo[2.2.2]octane-4-methanol 
• 869113-09-7 Umeclidinium bromide 
• 869112-31-2 4-[hydroxy(diphenyl)methyl]-1-(2-hydroxyethyl)-1-azoniabicyclo[2.2.2]octane bromide 
• 55022-91-8 quinuclidine-4-carbaldehyde 
• 26608-58-2 4-hydroxymethylquinuclidine 
• 22766-68-3 azabicyclo[2.2.2]octane-4-carboxylic acid ethyl ester 

Relevant articles and documents

Method for synthesizing intermediate of high-purity Umeclidinium bromide

The invention discloses a method for synthesizing intermediates 1-(2-chloroethyl) piperidine-4-formate and quinuclidin-4-carboxylic ester of Umeclidinium bromide, and particularly discloses a method for synthesizing an intermediate 1-(2-chloroethyl) piperidine-4-formate and quinuclidin-4-carboxylic ester of Umeclidinium bromide. According to the method, crude products of the intermediates 1-(2-chloroethyl) piperidine-4-formate and quinuclidin-4-carboxylate are purified in a molecular distillation or reduced pressure distillation mode, and the high-purity medical intermediates are obtained. Thepurification cost can be effectively reduced through molecular distillation or vacuum distillation, the yield is improved, and the product purity can reach 99% or above. According to the present invention, with the synthesis method, the 1-(2-chloroethyl) piperidine-4-formate and the quinuclidin-4-carboxylate are prepared, the process route is short, the amplified production is easy, and the yieldis high. The method has the characteristics of novel process, high yield, low cost, high product purity and the like.

A More Sustainable Process for Preparation of the Muscarinic Acetylcholine Antagonist Umeclidinium Bromide

A more sustainable process for the synthesis of the long-acting muscarinic acetylcholine antagonist umeclidinium bromide is described. Specifically, we report the synthesis of ethyl 1-(2-chloroethyl)-4-piperidinecarboxylate, a key intermediate in the prep

A 1 - (2 - chloroethyl) - 4 - piperidine carboxylic acid ester synthetic method

This invention relates to a 1 - (2 - chloroethyl) - 4 - piperidine carboxylic acid ester synthetic method, comprises the following steps, S1, compound I and ethylene oxide in the presence of open generates intermediate II; S2, intermediate II and thionyl chloride to carry out chlorination reaction, generating 1 - (2 - chloroethyl) - 4 - piperidine - a ester; synthetic route scientific, less side reaction, high reaction activity, all raw materials the homogeneous reaction, so that the reaction speed and conversion efficiency increase, the yield of 45% or more, the reaction less by-products, process using raw materials are easy, and the cost is low, no special operation process, high requirements on equipment, environment-friendly, can be large-scale production.

PROCESS FOR THE PREPARATION OF UMECLIDINIUM BROMIDE

The present invention discloses processes comprising a) reacting ethyl isonipecotate with 1 -bromo-2- chloroethane in the presence of an organic base in a solvent to form ethyl 1 -(2-chloroethyl)piperidine- 4-carboxylate (II) or a salt thereof. Process st

Quinuclidine derivative, method for preparing same and application of quinuclidine derivative

The invention relates to a quinuclidine derivative, a pharmaceutically acceptable salt, pro-drug and solvent compound of the quinuclidine derivative, a method for preparing the quinuclidine derivative, a drug composition with the quinuclidine derivative and the pharmaceutically acceptable salt, pro-drug and solvent compound and pharmaceutical application of the quinuclidine derivative. The quinuclidine derivative, the pharmaceutically acceptable salt, pro-drug and solvent compound, the method, the drug composition and the pharmaceutical application have the advantage that the compound is excellent in M3 receptor antagonist activity and accordingly can be used as a novel efficient drug for chronic obstructive pulmonary diseases.

Halogen-Bonded Supramolecular Capsules in the Solid State, in Solution, and in the Gas Phase

Supramolecular capsules were assembled by neutral halogen bonding (XB) and studied in the solid state, in solution, and in the gas phase. The geometry of the highly organized capsules is shown by an X-ray crystal structure which features the assembly of t

METHOD FOR THE PREPARATION OF 1-(2-HALOGEN-ETHYL)-4 PIPERIDINE-CARBOXYLIC ACID ETHYL ESTERS

The present invention refers to a process for the preparation of 1-(2-halogen-ethyl)-4-piperidinecarboxylic acid ethyl esters, in particular of 1-(2-chloroethyl)-4 piperidinecarboxylic acid ethyl ester, a versatile synthesis intermediate, particularly useful as an intermediate compound in the synthesis of umeclidinium.

CHEMICAL PROCESS

The present invention relates to a process for the preparation of umeclidinium bromide, and to processes for preparing intermediates used in the preparation of umeclidinium bromide.

Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists

A novel 4-hydroxyl(diphenyl)methyl substituted quinuclidine series was discovered as a very promising class of muscarinic antagonists. The structure-activity relationships of the connectivity of the diphenyl moiety to the quinuclidine core and around the ring nitrogen side chain are described. Computational docking studies using an homology model of the M3 receptor readily explained the observed structure-activity relationship of the various compounds. Compound 14o was identified as a very potent, slowly reversible M3 antagonist with a very long in vivo duration of bronchoprotection.

Muscarinic acetylcholine receptor antagonists

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.